ClinicalTrials.gg
Not yet recruitingNCT07791264Updated Aug 27, 2026

FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma

A Phase 1 interventional study of Biospecimen Collection and Computed Tomography in Glioblastoma, Malignant Glioma and Recurrent Glioblastoma, sponsored by City of Hope Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Glioblastoma by City of Hope Medical Center — 6 open to participants now, 12 under way, none of them phase 3. Glioblastoma · City of Hope Medical Center.

Planned enrollment
8th of 22
24 · median 19
Started
2027
the only one that year
Phase 1
20 of 23
4 open now
Primary completion
2028-08
later than 8 of 11 live
Registered
22nd of 23
by date

Among the 23 studies in Glioblastoma by City of Hope Medical Center, this one is the 8th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2027, is one of 20 in phase 1, reaches primary completion later than 8 of the 11 other live ones, and was the 22nd registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

6 of the 23 studies in Glioblastoma by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Glioblastoma by City of Hope Medical Center, or all of them as a file.
02

Study summary

This phase I trial tests the safety, side effects, best dose and how well FPS-ZM1 works for controlling post operative cerebral edema in patients with glioblastoma. FPS-ZM1 works by blocking the pathway that controls inflammation. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving FPS-ZM1 with or without dexamethasone may be safe and/or effective in controlling post operative cerebral edema in patients with glioblastoma.

Read the detailed description

PRIMARY OBJECTIVE:

I. Determine the maximum feasible dose (MFD) of RAGE antagonist FPS-ZM1 (FPS-ZM1) administered peri-operatively to participants with newly diagnosed or recurrent glioblastoma.

SECONDARY OBJECTIVES:

I. Assess the ability of FPS-ZM1 to control participants' symptoms of post-operative cerebral edema when administered as monotherapy.

II. Describe the systemic pharmacokinetics and central nervous system (CNS) penetration of FPS-ZM1 based on concentrations of FPS-ZM1 in peripheral blood, cerebrospinal fluid (CSF), brain tumor tissue and resection cavity fluid (when obtainable).

III. Characterize cytokine concentrations over time in brain interstitial fluid, peripheral blood and resection cavity fluid (when obtainable) by dose level.

IV. Assess for evidence of RAGE inhibition in tumor tissue, CSF, brain interstitial fluid, resection cavity fluid (when obtainable) and peripheral blood by dose level.

V. Qualitatively and quantitatively assess changes in volume of cerebral edema on pre-operative brain magnetic resonance imaging (MRIs) and brain MRIs performed on post-operative Days 2 and 14 across dose levels.

OUTLINE: This is a dose-escalation study of FPS-ZM1 in combination with fixed-dose dexamethasone. Patients are assigned to 1 of 2 arms.

ARM I (DOSE LEVELS 1-3): Starting 2 days prior to surgery, patients receive FPS-ZM1 orally (PO) daily (QD) until post operative day 11, and dexamethasone intravenously (IV) or PO QD taper until post operative day 14, in the absence of disease progression or unacceptable toxicity. On day of surgery patients undergo standard of care resection and, if possible, undergo placement of a temporary peritumoral microdialysis catheter and intracavity drain for collection of dialysate and intracavity fluid. Patients undergo urine sample collection during screening, lumbar puncture with CSF collection and computed tomography (CT) scan on study and brain MRI, and blood sample collection throughout the study.

ARM II (DOSE LEVEL 4): Starting 2 days prior to surgery, patients receive FPS-ZM1 PO QD and, if needed for physiologic replacement, a smaller dose of dexamethasone IV or PO QD until post operative day 11, in the absence of disease progression or unacceptable toxicity. On day of surgery patients undergo standard of care resection and, if possible, undergo placement of a temporary peritumoral microdialysis catheter and intracavity drain for collection of dialysate and intracavity fluid. Patients undergo urine sample collection during screening, lumbar puncture with CSF collection and CT scan on study and brain MRI, and blood sample collection throughout the study.

After completion of study treatment, patients are followed up at day 30.

03

Conditions studied

  • Glioblastoma
  • Malignant Glioma
  • Recurrent Glioblastoma
  • Recurrent Malignant Glioma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented given by the participant. Non-English speaking adults are eligible for participation if they have the capacity to understand and consent to the study procedures
  • Age: ≥ 18 years
  • Performance Status (KPS) ≥ 70%
  • confirmed glioblastoma or radiographic findings consistent with a high grade glioma
  • Newly diagnosed or recurrent tumor
  • The patient is planning to undergo a standard-of-care craniotomy for gross total resection of enhancing tumor
  • The patient's pre-operative brain MRI shows the presence of mild to moderate cerebral edema, defined as a midline shift of less than 10 mm
  • Dose Levels 1-3 participants: If taking more than a total of 6 mg a day of dexamethasone at the time of signing the consent form, it is anticipated by the neurosurgeon that the participant will be able to decrease their dose of dexamethasone to 6 mg daily by 4 days before the surgery (pre-operative Day -4)
  • Dose Level 4 participants: If taking more than 1 mg a day of dexamethasone at the time of signing the consent form, it is anticipated by the neurosurgeon that the participant will be able to taper their dose of dexamethasone to 1 mg daily or less by pre-operative Day -4
  • The patient is not planning to be in another clinical trial during the study period
  • The patient has recovered from any acute toxic effects (except alopecia) to ≤ grade 1 of prior anti-cancer therapy
  • No limit to prior number of therapies. The following time periods must have elapsed prior to the start of study treatment: 6 weeks from nitrosourea-containing chemotherapy, 4 weeks from non-nitrosourea-containing cytotoxic chemotherapy (except 23 days from last daily dose of temozolomide taken in a 5 of 28 day regimen, 5 half-lives from last dose of a targeted agent, and 4 weeks from the last dose of bevacizumab). There is no time period requirement for prior radiation therapy
  • (ANC) ≥ 1,000/mm\^3
  • ≥ 100,000/mm\^3
  • ≥ 9g/dL
  • Total ≤ 1.5 X (ULN) (unless has Gilbert's disease)
  • (AST) ≤ 1.5 x ULN
  • Alanine aminotransferase (ALT) ≤ 1.5 x ULN
  • Estimated (eGFR) ≥ 60 mL/min
  • (INR) OR Prothrombin (PT) ≤ 1.5 x ULN
  • Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 x ULN
  • interval (QTc) ≤ 450 ms

    • Must have a Fridericia's corrected QT interval (QTcF) ≤ 450 msec calculated with Fridericia formula
  • (LVEF) ≥ 50%
  • People of who have uteri: negative urine or serum pregnancy test
  • :

    • Agreement by participants of childbearing potential or participants who are partners of people with childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy.

Contraception guidance (as per the information included in the informed consent document):

  • Acceptable medically effective forms of birth control are:

    • Surgical sterilization (tubal ligation or hysterectomy, or vasectomy, as applicable),
    • Double-barrier methods (i.e. condoms, diaphragm, cervical cap, or sponge used with spermicidal gel or foam),
    • Intrauterine device (IUD) (i.e. Progestin, Copper),
    • Hormonal Contraceptives (Birth control patches, implants, pills, rings, or injections)

Exclusion criteria

Exclusion Criteria:

  • The patient is taking a medication that is a strong or moderate inducer or inhibitor of major CYP450 isoenzymes and drug transporters, and the patient is not able to stop that medication at least 14 days prior to start of study treatment
  • The patient has a risk factor for torsades de pointes, such as structural heart disease (history of myocardial infarction, congestive heart failure, left ventricular hypertrophy), electrolyte abnormalities (hypokalemia, hypomagnesemia), bradycardia or heart blocks, or a family history of Long syndrome
  • The patient is taking a medication that prolongs the QT/QTc interval and is not able to stop that medication at least 14 days prior to start of study treatment
  • The patient is unwilling to stop taking herbal medications prior to the start of study treatment
  • The patient is taking a hepatic enzyme-inducing anti-seizure medication within 14 days prior to start of study treatment
  • Patient is planning to participate in clinical trial or start a new therapy for their brain tumor during the study period: Day -2 to Day 14
  • Patient has not recovered from toxicities of prior therapy (must be grade 1 or less) except alopecia
  • Adults who lack the capacity to provide , including individuals who would require consent from a Legally Authorized Representative (LAR)
  • uncontrolled illness
  • Active infection requiring antibiotics
  • Participants with (HIV) are excluded due to concerns about inadvertent augmentation of infectious and/or inflammatory activity
  • Undergoing treatment for another cancer
  • Issues with tolerating oral medication (e.g. inability to swallow, malabsorption issues, ongoing nausea or vomiting)
  • Chronic or active viral infection of the CNS
  • Participant is pregnant or breastfeeding
  • Coagulopathy or bleeding disorder
  • Inability to undergo a brain MRI
  • Inability to tolerate dexamethasone
  • Any other condition that would, in the investigator's judgment, contraindicate participation in the clinical study due to safety concerns with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Arm I (FPS-ZM1 and dexamethasone)

    Starting 2 days prior to surgery, patients receive FPS-ZM1 PO QD until post operative day 11, and dexamethasone IV or PO QD taper until post operative day 14, in the absence of disease progression or unacceptable toxicity. On day of surgery patients undergo standard of care resection and, if possible, undergo placement of a temporary peritumoral microdialysis catheter and intracavity drain for collection of dialysate and intracavity fluid. Patients undergo urine sample collection during screening, lumbar puncture with cerebrospinal fluid collection and CT scan on study and brain MRI, and blood sample collection throughout the study.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Drug: Dexamethasone · Procedure: Invasive Procedure · Procedure: Magnetic Resonance Imaging · Drug: RAGE Antagonist FPS-ZM1 · Procedure: Resection

  • Experimental
    Arm II (FPS-ZM1)

    Starting 2 days prior to surgery, patients receive FPS-ZM1 PO QD and, if needed for physiologic replacement, a smaller dose of dexamethasone IV or PO QD until post operative day 11, in the absence of disease progression or unacceptable toxicity. On day of surgery patients undergo standard of care resection and, if possible, undergo placement of a temporary peritumoral microdialysis catheter and intracavity drain for collection of dialysate and intracavity fluid. Patients undergo urine sample collection during screening, lumbar puncture with cerebrospinal fluid collection and CT scan on study and brain MRI, and blood sample collection throughout the study.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Drug: Dexamethasone · Procedure: Invasive Procedure · Procedure: Magnetic Resonance Imaging · Drug: RAGE Antagonist FPS-ZM1 · Procedure: Resection

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood, dialysate, intracavity fluid, and urine sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • Given IV or PO

    Also known as: Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex

  • ProcedureInvasive Procedure

    Undergo placement of a temporary peritumoral microdialysis catheter

    Also known as: Invasive

  • ProcedureInvasive Procedure

    Undergo intracavity drain placement

    Also known as: Invasive

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • DrugRAGE Antagonist FPS-ZM1

    Given PO

    Also known as: FPS ZM1, FPS-ZM1, FPSZM1, RAGE Inhibitor FPS-ZM1

  • ProcedureResection

    Undergo resection surgery

    Also known as: Surgical Resection

06

What researchers measure

Primary outcomes

  1. RAGE Antagonist FPS-ZM1 (FPS-ZM1) related adverse events

    Assessed per Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.

    Time frame: Up to 30 days post surgery

  2. Dose limiting toxicity rate

    Assessed per CTCAE version 6.0.

    Time frame: Up to 30 days post surgery

Secondary outcomes

  1. Doses of dexamethasone taken post-operatively by study participants on dose Level 4

    Time frame: Up to 30 days post surgery

  2. FPS-ZM1 concentrations in enhancing tumor tissue

    Time frame: Up to 30 days post surgery

  3. FPS-ZM1 concentrations in non-enhancing tumor tissue

    Time frame: Up to 30 days post surgery

  4. FPS-ZM1 concentrations in cerebrospinal fluid (CSF)

    Time frame: Up to 30 days post surgery

  5. FPS-ZM1 concentrations in resection cavity fluid

    Time frame: Up to 30 days post surgery

  6. Cytokine concentrations in brain interstitium

    Time frame: Up to 30 days post surgery

  7. Cytokine concentrations in peripheral blood

    Time frame: Up to 30 days post surgery

  8. Cytokine concentrations in resection cavity fluid

    Time frame: Up to 30 days post surgery

  9. Concentrations of RAGE ligands in brain extracellular fluid

    Time frame: Up to 30 days post surgery

  10. Concentrations of RAGE ligands in CSF

    Time frame: Up to 30 days post surgery

  11. Concentrations of RAGE ligands in resection cavity fluid

    Time frame: Up to 30 days post surgery

  12. Concentrations of RAGE ligands in peripheral blood

    Time frame: Up to 30 days post surgery

  13. Expression of activating markers on tumor infiltrating lymphocytes

    Time frame: Up to 30 days post surgery

  14. Expression of activating markers on myeloid cells

    Time frame: Up to 30 days post surgery

  15. Expression of activating markers on lymphocytes in resection cavity fluid

    Time frame: Up to 30 days post surgery

  16. Expression of activating markers on myeloid cells in resection cavity fluid

    Time frame: Up to 30 days post surgery

  17. Expression of activating markers on lymphocytes in peripheral blood

    Time frame: Up to 30 days

  18. Expression of activating markers on myeloid cells in peripheral blood

    Time frame: Up to 30 days post surgery

  19. T1 enhancing tumor volume from segmented T1-weighted magnetic resonance imaging (MRI)

    Time frame: Up to 30 days post surgery

  20. Mean intratumoral perfusion from dynamic contrast enhanced (DCE)-MRI

    Time frame: Up to 30 days post surgery

  21. Interstitial fluid flow from DCE-MRI

    Time frame: Up to 30 days post surgery

  22. T2-FLAIR enhancing edema from segmented T2-FLAIR MRI

    Time frame: Up to 30 days post surgery

  23. Mean intratumoral blood volume from relative cerebral blood volume as calculated from DSC-MRI

    Time frame: Up to 30 days post surgery

  24. Mean intratumoral tissue density as measured by the apparent diffusion coefficient derived from diffusion-weighted MRI

    Time frame: Up to 30 days post surgery

  25. Mean intratumoral lactate and glutatione concentration as measured by multiplexed MR spectroscopy

    Time frame: Up to 30 days post surgery

  26. FPS-ZM1 plasma pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)

    Time frame: Up to 30 days post surgery

  27. FPS-ZM1 plasma pharmacokinetics: Area Under the Plasma Concentration-Time Curve (AUC)

    Time frame: Up to 30 days post surgery

  28. FPS-ZM1 plasma pharmacokinetics: Terminal Elimination Half-Life (t½)

    Time frame: Up to 30 days post surgery

  29. FPS-ZM1 plasma pharmacokinetics: Clearance (CL)

    Time frame: Up to 30 days post surgery

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Aug 2028, 18 months later.

Of 239 non-industry phase 1 interventional studies under Glioblastoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 18 months is below that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2026
First posted
Aug 27, 2026
StartEst.
Feb 17, 2027
Primary completionEst.
Aug 28, 2028
CompletionEst.
Aug 28, 2028
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07791264
Responsible party
Sponsor
First posted
Aug 27, 2026
Start date
Feb 17, 2027 (estimated)
Primary completion
Aug 28, 2028 (estimated)
Completion
Aug 28, 2028 (estimated)
Last update
Aug 27, 2026

Study contacts

Jana L Portnow
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion